Document text
Principal Investigator: Valerian Nakaar
Organization: CAROGEN CORPORATION
Fiscal Year: 2022
Award: $263,991
Funding agency: National Center for Immunization and Respiratory Diseases
PROJECT ABSTRACT
Current vaccines are mainly strain-specific and have limited efficacy in preventing new, potentially pandemic
influenza strains. Interest in a universal influenza vaccine (UIV) to prevent future pandemics has been greatly
boosted by the success of mRNA-based coronavirus vaccines. However, developing a UIV has been particularly
challenging for two reasons: (1) the failure of immunization to induce broadly neutralizing antibodies against
conserved epitopes and (2) the lack of a safe and effective vaccine platform to induce broad and long-lasting
immunity. Virus-like vesicles (VLVs) are infectious, self-propagating alphavirus-vesiculovirus hybrid vaccine vectors
that can be engineered to express foreign antigens to elicit a protective immune response. These self-amplifying
RNA replicons are safe, highly immunogenic, and scalable to produce. The goal of this proposal is to rationally
design and engineer a VLV to express multiple flu antigens and thus induce broad and long-lasting immunity. As
shown in our published studies, the ectodomain of M2 (M2e) and domains of the immunodominant hemagglutinin
(HA) globular head can elicit robust antibody responses that mitigate disease and protect mice from lethal challenge.
We have also established that VLV carrying RNA encoding one or more of the major antigens of hepatitis B virus
(HBV) in a single open reading frame drives a broad multi-specific immune response that results in substantial
clearance of HBV in the mouse liver. Recent improvements in the development of this VLV immunotherapy vector
enhanced gene expression with a concomitant increase in both T-cell responses and antibodies. In preliminary
studies, we found that signal sequences promote efficient secretion of recombinant proteins that are highly
conserved among influenza strains, i.e., M2e, nucleoprotein, the long-alpha helix (LAH) of subunit 2 of HA, and
fusion peptide from VLV-infected cells. Our initial single-dose screening of individual flu antigen VLV vaccines
(sponsored by the Respiratory Diseases Branch of NIAID/NIH) showed promising mitigation of disease progression.
A reduction in lung virus titer was apparent in HA2 VLV vaccines. Albeit low, viral neutralizing titers (VNTs) were
present in all immunized groups (>1:16). In addition, our serological data show an increased induction of IgG1 and
IgG2a in most flu-based VLV-immunized groups. These virus-specific IgG isotypes correlate better with vaccine
efficacy than neutralization alone. We will carry out three specific aims: Aim 1. Characterize the immunogenicity of
VLV-Multi-Ag constructs in mice. Aim 2. Evaluate vaccine efficacy in a lethal influenza mouse model. Aim 3.
Evaluate prime-boost regimens to optimize flu-specific immune responses. The results of these studies will provide
initial data on the feasibility of developing a UIV. VLV-mediated delivery of multi-antigens targeting multiple epitopes
of conserved proteins may provide an effective strategy to prevent infection with influenza virus. The proposed
research is highly significant because an effective vaccine is needed to prevent both influenza epidemics and to
enhance our ability to respond to future pandemics.
Terms: <7S Gamma Globulin><Address><Alpha Virus><Alphavirus><Antibodies><Antibody Response><Antigen Targeting><Antigenic Determinants><Antigens><Assay><Automobile Driving><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Body Weight decreased><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><Cell Body><Cell Mediated Immunology><Cell-Mediated Immunity><Cells><Cellular Immunity><Cessation of life><Cyclic GMP><Data><Death><Disease><Disease Progression><Disorder><Dose><ELISA><ELISPOT><Engineering><Enzyme-Linked Immunosorbent Assay><Epidemic><Epitopes><Failure><Flu epidemic><Future><G-Proteins><GTP-Binding Proteins><GTP-Regulatory Proteins><Gene Expression><Goals><Grippe><Group A Arboviruses><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Regulatory Proteins><Guanosine Cyclic Monophosphate><H3N2><H3N2 Virus><HBAg><HBV><HBV Vaccine><HBV antigen><Head><Health><Hemagglutinin><Hepatitis B Antigens><Hepatitis B Vaccines><Hepatitis B Virus><Hepatitis B virus vaccine><Homologous Serum Hepatitis Virus><Hospital Admission><Hospitalization><Human><Hybrids><IgG><IgG1><Immune mediated therapy><Immune response><Immunity><Immunization><Immunize><Immunodominant Antigenic Determinants><Immunodominant Determinants><Immunodominant Domains><Immunodominant Epitopes><Immunodominant Regions><Immunodominant Sites><Immunoglobulin G><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunologically Directed Therapy><Immunostimulation><Immunotherapeutic agent><Immunotherapy><In Vitro><Individual><Infection><Infection prevention><Influenza><Influenza A Virus, H3N2 Subtype><Influenza Vaccines><Influenza Virus><Liver><Lung><Lung Respiratory System><Measures><Mediating><Messenger RNA><Mice><Mice Mammals><Modern Man><Murine><Mus><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Non-Polyadenylated RNA><Nucleoproteins><ORFs><Open Reading Frames><Peptide Signal Sequences><Peptides><Persons><Phenotype><Prevent infection><Protein Coding Region><Proteins><Publishing><RNA><RNA Gene Products><RNA amplification><Recombinant Proteins><Regimen><Replication Unit><Replicon><Research><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Ribonucleic Acid><Serology><Serotyping><Signal Peptide><Signal Sequences><Specificity><Staining method><Stains><T cell response><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Technology><Testing><United States National Institutes of Health><VSV><Vaccination><Vaccines><Vesicle><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Vesiculovirus><Viral><Viral Antigens><Virus><Weight Loss><Weight Reduction><alpha helix><base><body weight loss><cGMP><coronavirus vaccine><develop a vaccine><develop vaccines><development of a vaccine><driving><enzyme linked immunoassay><enzyme linked immunospot assay><evaluate vaccines><flu><flu infection><flu serotype><flu strain><flu subtype><flu vaccine><flu viral strain><flu virus infection><flu virus pandemic><flu virus strain><flu virus vaccine><hepatic body system><hepatic organ system><host response><immune drugs><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunogenic><immunogenicity><immunologic preparation><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><improved><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza epidemic><influenza infection><influenza serotype><influenza strain><influenza subtype><influenza viral strain><influenza virus infection><influenza virus pandemic><influenza virus strain><influenza virus vaccine><influenzavirus><innovate><innovation><innovative><interest><mRNA><mortality><mouse model><murine model><neutralizing antibody><novel><pandemic><pandemic disease><pandemic flu><pandemic influenza><pandemic strain of influenza><plasmid DNA><plasmid vaccine><prevent><preventing><protein signal sequence><pulmonary><rational design><respiratory><screening><success><thymus derived lymphocyte><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccine against coronavirus><vaccine against flu><vaccine against hepatitis B><vaccine against influenza><vaccine development><vaccine efficacy><vaccine evaluation><vaccine platform><vaccine screening><vaccine testing><vector><vector vaccine><virus antigen><virus development><wt-loss><α-helix>